John Bernard Buse - the UNC Department of Medicine

More documents

Recommendations

Info

Buse, Curriculum Vitae p. 22 of 29 Updated: August 2008 Prior Grant Support (UNC only): 2005 PI, Clinical Evaluation of the Safety and Feasibility of the Investigational BD Continuous Glucose Monitoring Sensor (Becton-Dickinson Research Laboratories) PI, Multicenter, double-blind, randomized, placebo controlled, dose ranging phase 2 study to investigate efficacy, safety, tolerability and pharmacokinetics of the DPP-IV inhibitor RO0730699 in patients with type 2 diabetes, who are treated with a stable dose of metformin. (Hoffman-LaRoche) 2004 PI, A Study of the Safety and Effectiveness of the DexCom Continuous Glucose Monitor in Patients with Type 1 Diabetes Mellitus (DexCom) PI, A Randomized, Double-blind, Placebo Controlled, Rising Dose, Multicenter Study to Evaluate the Safety and Efficacy of 90 Days of 300 or 600 mg Daily Subcutaneous Injections of INGAP peptide in Type 1 Diabetes Mellitus Patients. (Quintiles) PI, A Randomized, Double-blind, Placebo Controlled, Rising Dose, Multicenter Study to Evaluate the Safety and Efficacy of 90 Days of 300 or 600 mg Daily Subcutaneous Injections on INGAP peptide in Type 2 Diabetes Mellitus Patients. (Quintiles) PI, Anhydroglucitol (1,5-AG) and Postprandial Hyperglycemia as Measured by Continuous Glucose Monitoring System (CGMS) in Inadequately Controlled Patients with Diabetes (Tomen, Japan) PI, A study of the safety and effectiveness of the DexCom Continuous Glucose Monitor in patients with type 1 diabetes mellitus. (Dexcom) 2003 PI, An open-Label Study to Examine the Long Term effect on Glucose Control and Safety and Tolerability of AC2993 Given Two Times a Day to Subjects with Type 2 Diabetes Mellitus (Amylin) Co-investigator, A phase 3 randomized, double blind, placebo controlled multicenter trail to evaluate the safety and efficacy of BMS 298585 in combination with metformin therapy in subjects with type 2 diabetes who have inadequate glycemic control on metformin therapy alone. (Bristol Myers Squibb) 2002 PI, Retrospective Study for the Collection of DNA from Patients Previously Enrolled in Study 1014 (Pfizer) Co-investigator, 12-week, Multinational, Mulitcenter, Controlled Open 1:1:1 Randomized, Parallel Clinical Trial to Assess Noninferiorty Between Pre-and Post - Meal Administration of HMR 1964 and Pre-Meal Regular Human Insulin in Subjects with Type 1 Diabetes Mellitus Receiving Insulin Glargine as the Basal Insulin Therapy (Aventis) PI, A Phase 3 Randomized Triple Blind Parallel Group Long Term Placebo Controlled Multicenter Study to Examine the Effect on Glucose Control of AC2993 Given two times a day in subjects with Type 2 Diabetes Mellitus Treated with Metformin Alone (Amylin) PI, A Phase 3 Randomized Triple Blind Parallel Group Long Term Placebo Controlled Multicenter Study to Examine the Effect on Glucose Control of AC2993 Given two times a day in subjects with Type 2 Diabetes Mellitus Treated with Sulfonylurea Alone (Amylin) Co-investigator, A 26-week multinational, mulitcenter, open clinical extension trial to assess 1 year safety of HMR 1964 compared with regular insulin injected subcutaneously in subjects with type 2 diabetes mellitus also using NPH Insulin and previously participating in study HMR 1964-3002 (Aventis)
Buse, Curriculum Vitae p. 23 of 29 Updated: August 2008 PI, A Phase 3 Randomized Triple Blind Parallel Group Long Term Placebo Controlled Multicenter Study to Examine the Effect on Glucose Control of AC2993 Given two times a day in subjects with Type 2 Diabetes Mellitus Treated with Metformin and Sulfonylurea (Amylin) PI, A Randomized Triple-Blind Placebo-Controlled Multicenter Study to Investigate the safety of Pramlintide Treatment Employing Pramlintide Dose-Titration Followed by Insulin Dose Optimization in Subjects with Type 1 Diabetes (Amylin) Co-investigator, The Anthem Study; Advicor in the Treatment of Diabetic Patients with Dyslipidemia Using Thiazolidinedione (KOS) PI, A Randomized, Double-Blind, Comparator-Controlled Study of Pioglitazone HCI vs Glyburide in the Treatment of Subjects with Type 2 (Non-Insulin Dependent) Diabetes Mellitus and Mild Cardiac Disease (NYHA I) (Takeda) 2001 Co-investigator, A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Examine the Effect of Glucose Control of AC 2993 (0.08/ug/kg) Given Threes Times a Day Versus Twice a Day for 29 Days in Subjects with Type 2 Diabetes Mellitus Treated with Sulfonylureas and/or Metformin (Amylin) PI, Clinical Effectiveness of the Diasensor 2000 Noninvasive Glucose Meter used in a De-Centralized Environment (Biocontrol) PI, Single dose and 34-Day Tolerance Study of INGAP Peptide in Insulin Deficient Patients (GMP) 2000 Co-investigator, Cardiovascular Health in Children and Youth (NIH, NINR) PI, A Randomized, Multi-Center, Placebo Controlled, Double-Blind, Parallel Group Clinical Trial to Assess the Effect of Three Months Repeated Daily Oral 1200 mg Doses of D-Chiro-Inositol (INS-1), in Combination with Oral Sulfonylureas Control and Lipid Profiles in Patients with Type 2 Diabetes. (Insmed) PI, Pioglitazone Versus Rosiglitazone in Subjects with Type 2 Diabetes Mellitus and Dyslipidemia. (Lilly) PI, Safety of Pulmonary Insulin in Patients with Type 2 Diabetes (Lilly) PI, A Long-Term, Double-Blind, Placebo Controlled, Parallel Group Study of Zenarestat (CI-1014) in Diabetic Patients at Risk of Foot Ulcer. (Parke-Davis) PI, A 12-Week, Double-Blind, Placebo-Controlled, Multi-Center Study to Compare the Effect of Zenerstat (CI-1014) with Enalapril on Microalbuminuria in Diabetes Patients. (Parke-Davis) PI, A 12-month, Multi-Center, Open-Label Extension to Protocol 1014-001 to Evaluate the Safety of Zenarestat (CI-1014) in the Treatment of Diabetic Neuropathy. (Parke- Davis) PI, A 20-Week, Double-Blind, Randomized, Active-Controlled, Multicenter Study Comparing Efficacy and Safety of Troglitazone Plus Metformin or Rosiglitazone Plus Metformin to Metformin Plus Placebo in Type 2 Diabetic Patients Not Optimally Controlled on Metformin. (Parke-Davis) PI, A Multicenter, Randomized, Double-Blind, Parallel Group, Clinical Evaluation of Oral GI262570 Sodium Tablets (2.5mg, 5 mg and 7.5mg) in Combination with Metformin for 26 Weeks Duration in Subjects with Type 2 Diabetes Mellitus who Are Inadequately Controlled on a Maximum Dose of Metformin. (Glaxo-Wellcome)
Page 1 and 2: CURRICULUM VITAE Personal Informati
Page 3 and 4: Buse, Curriculum Vitae p. 3 of 29 U
Page 11 and 12: Buse, Curriculum Vitae p. 11 of 29
Page 21: Buse, Curriculum Vitae p. 21 of 29
Page 29: Buse, Curriculum Vitae p. 29 of 29

John Bernard Buse - the UNC Department of Medicine

Create successful ePaper yourself

Delete template?

Save as template?